查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
再生医学市场规模及预测（2021-2031年），全球及区域份额、趋势和成长机会分析报告涵盖范围：按产品类型、应用和地理划分
市场调查报告书
商品编码
1858555

再生医学市场规模及预测（2021-2031年），全球及区域份额、趋势和成长机会分析报告涵盖范围：按产品类型、应用和地理划分

Regenerative Medicine Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage:By Product Type, Application, and Geography
出版日期: | 出版商: The Insight Partners | 英文 231 Pages | 订单完成后即时交付

价格

根据我们最新发布的题为《2031年全球再生医学市场预测－按产品类型和应用分類的分析》的研究报告，再生医学市场规模将从2024年的205.5亿美元增长到2031年的751.6亿美元，复合年增长率（CAGR）预计为20.3%。再生医学市场的成长主要归因于慢性疾病盛行率的上升、人口老化以及先进再生疗法的引入。

再生医学是生物医学的一个分支，专注于修復、替换或再生受损或病变的细胞、组织或器官，以恢復其正常功能。它结合了干细胞疗法、组织工程、基因疗法和生物材料等多种方法，以促进癒合和再生。

北美再生医学市场分为美国、加拿大和墨西哥三个部分。美国占最大的市场份额，其次是加拿大。根据美国疾病管制与预防中心（CDC）统计，美国每40秒就会发生一起心臟病发作，每年约有80.5万人患有此病。癌症是导致发病率和死亡率的主要原因，不仅造成巨大的医疗成本，也严重影响病患的生活品质。慢性病和退化性疾病的日益普遍，使得人们对再生疗法等新型治疗方法的需求不断增长。

再生医学在北美常见疾病的治疗方面具有变革性潜力，尤其是在心血管疾病、糖尿病和某些类型的癌症方面。干细胞疗法、基因编辑和组织工程的进展在这些领域展现出良好的前景。多种CAR-T细胞疗法已获得FDA批准，用于治疗血液系统恶性肿瘤，例如多发性骨髓瘤和淋巴瘤。

慢性病和退化性疾病负担日益加重，推动了再生医学领域在研究、生物製造和人才培养方面的投资。这个生态系统促进了快速创新，并提高了治疗方案的可及性和精细化程度。 2022年1月，总部位于美国的自主细胞疗法生产公司Cellino Biotech, Inc.完成了由拜耳旗下Leaps by Bayer领投的8000万美元A轮融资，8VC和洪堡基金也参与了此次融资。 Cellino的创新製造平台结合了人工智慧和雷射技术，实现了细胞疗法生产的自动化，旨在降低成本并提高规模化生产能力。这项投资为Leaps by Bayer提供了一个独特的机会，使其能够支持先进疗法的开发，从而提高患者获得细胞治疗的机会。

在北美，美国占据再生医学市场的重要份额。 2024年，美国在北美再生医学市场占据主导地位。根据美国疾病管制与预防中心（CDC）的数据显示，2023年，76.4%的美国成年人（超过1.94亿人）至少患有一种慢性病。其中超过一半（51.4%，即1.31亿人）报告患有两种或两种以上慢性疾病。成年人中至少患有一种慢性疾病的比例从72.3%上升至76.4%。患有两种或两种以上慢性疾病的成年人比例从47.3%上升至51.4%。

根据阿兹海默症协会预测，到2025年，美国将有超过720万65岁及以上的老年人患有阿兹海默症，到2050年，这一数字预计将增长至1270万。心血管疾病、癌症和神经退化性疾病等慢性疾病会导致组织或器官的不可逆损伤，因此这些患者是干细胞疗法、组织工程和基因疗法等再生疗法的理想对象。再生医学在以下方面展现出巨大潜力：心臟病发作后恢復心臟功能、再生退化性关节疾病中的软骨以及替换神经退化性疾病中受损的神经元。在美国，间质干细胞（MSCs）常用于治疗退化性疾病以及某些皮肤、骨骼和软骨疾病。

美国政府正透过监管创新、加速审批流程、直接资助和合作技术支持，推动再生疗法的研发和批准。截至2025年中期，已有超过80项再生医学先进疗法（RMAT）获得认定，有助于加速脊髓损伤和心臟衰竭等疾病的临床进展。 2023年，美国FDA批准了包括针对罕见疾病的基因编辑疗法在内的多种细胞和基因疗法。例如，用于治疗镰状细胞贫血症的exagamglogene autotemcel（Casgevy）和lovotibeglogene autotemcel，以及用于治疗重度血友病A的valoctocogene roxaparvovec等疗法均已获得FDA批准，凸显了基因疗法在应对罕见疾病挑战方面的巨大潜力。因此，慢性病发病率的不断上升，以及为促进再生技术应用而持续进行的研究和审批倡议，正在推动美国再生医学市场的成长。

将人工智慧应用于再生医学，将在未来带来市场机会

将人工智慧 (AI) 应用于再生医学，能够促进药物发现，改善个人化疗法，并加速研发进程。 AI 驱动的技术有助于处理复杂的生物资料并优化生产流程，从而提高再生疗法的效率。 Aspen Neuroscience 的 ANPD-001 目前正处于帕金森氏症 II 期临床试验阶段，它是一种开创性的 AI 赋能再生疗法。该疗法利用 AI 和机器学习 (ML) 将患者的皮肤细胞重编程为多巴胺能神经元。专有的基于 AI 的基因组检测可确保细胞质量，从而实现更安全、更个性化的治疗。这种方法展示了 AI 验证如何提高再生医学产品的精准性和生物安全性，同时降低排斥风险。

多家新创公司进一步印证了这个趋势。阿根廷公司 MesencHyal-T 利用人工智慧驱动的细胞疗法，致力于骨骼再生。该公司在其可扩展的生产流程中运用机器学习技术，以标准化干细胞扩增并提高细胞的成骨潜能。此外，该公司还与医院和研究中心合作，以加速临床应用，展现了人工智慧如何帮助发现、实际应用以及结果预测。同样，总部位于英国的 Trogenix 公司将基因组学、生物资讯学和机器学习技术整合到其合成超级增强子病毒免疫疗法中，用于精准基因控制和靶向再生治疗，以治疗癌症和老化相关组织损伤。

人工智慧驱动的平台辅助产品上市，加速候选药物的研发。人工智慧药物发现领域的领导企业Insilico Medicine凭藉其用于治疗特发性肺纤维化的小分子候选药物INS018_055取得了里程碑式的进展。该药物是第一个完全由人工智慧发现和设计的、进入II期临床试验的药物。 Insilico与製药巨头赛诺菲达成了一项价值12亿美元的合作协议，该协议利用Insilico的人工智慧平台来识别新的目标并预测临床结果，凸显了以人工智慧驱动的再生医学解决方案为中心的合作生态系统。

在製造和治疗设计方面，像总部位于美国的Shinobi Therapeutics这样的公司利用人工智慧平台开发免疫逃脱诱导多能干细胞（iPSC）疗法，其特点是经过基因编辑，可以逃避免疫系统的检测。这种策略提供了适用于肿瘤、糖尿病和自体免疫疾病的现成再生疗法，展现了人工智慧如何简化先进再生产品所需的复杂基因工程。

人工智慧有助于克服再生医学领域的许多挑战，例如高昂的研发成本和漫长的研发週期。它能够提升预测建模、品质控制和生产规模化能力。人工智慧演算法分析大量资料集，预测患者对干细胞疗法的具体反应，从而帮助制定个人化治疗方案并改善临床疗效。产业预测显示，到2025年，人工智慧的应用将大幅成长，成为全球再生医学个人化治疗方案的基础。

人工智慧在再生医学领域的应用代表着一项突破性趋势。人工智慧能够简化疗法研发流程，并提升个人化、品质和临床疗效。这种方法将使再生医学在未来几年迎来前所未有的成长，并造福更多患者，凸显了尖端技术与生物创新融合的趋势，从而彻底革新再生疗法的设计、测试和应用。

在编制再生医学市场报告时，参考的主要和次要来源包括美国食品药物管理局 (FDA)、药品和保健产品监管局 (MHRA) 以及再生医学联盟 (ARM)。

目录

第一章：引言

第二章：执行概要

  • 分析师市场展望
  • 市场吸引力

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基础数字：
    • 数据三角测量：
    • 国家层面资料：
  • 假设和局限性

第四章：再生医学市场概况

  • 概述
  • PEST分析

第五章：再生医学市场－主要市场动态

  • 再生医学市场－主要市场动态
  • 市场驱动因素
    • 慢性疾病盛行率上升和人口老化
    • 先进再生疗法的介绍
  • 市场限制
    • 再生治疗中的高成本障碍
  • 市场机会
    • 对个人化和精准医疗的需求激增
  • 未来趋势
    • 人工智慧在再生医学的应用
  • 驾驶员和安全带的影响：

第六章：再生医学市场－全球市场分析

  • 2021-2031年再生医学市场收入
  • 再生医学市场预测分析

第七章：再生医学市场分析－依产品类型划分

  • 细胞製品
  • 基因疗法
  • 组织工程

第八章：再生医学市场分析－按应用领域划分

  • 肿瘤学
  • 神经系统疾病
  • 伤口癒合和皮肤再生
  • 眼科
  • 骨科和肌肉骨骼
  • 免疫学
  • 遗传性疾病
  • 其他的

第九章：再生医学市场—地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：竞争格局

  • 关键参与者热力图分析
  • 公司定位与集中度

第十一章：行业概况

  • 概述
  • 产品上市，产品审批
  • 扩张及其他策略发展

第十二章：公司简介

  • Bristol-Myers Squibb Co
  • Novartis AG
  • Johnson & Johnson
  • Daiichi Sankyo Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Japan Tissue Engineering Co., Ltd.
  • Bluebird Bio Inc
  • JCR Pharmaceuticals Co. Ltd.
  • Vertex Pharmaceuticals Inc
  • Ferring Pharmaceuticals
  • CSL Behring LLC
  • BioMarin Pharmaceutical Inc.

第十三章：附录

Product Code: TIPRE00040655

According to our new research study on "Regenerative Medicine Market Forecast to 2031 -Global Analysis - by Product Type, and Application," the market is anticipated to grow from US$ 20.55 billion in 2024 to US$ 75.16 billion by 2031; the market is expected to register a CAGR of 20.3%. The regenerative medicine market growth is attributed to the rising prevalence of chronic disorders, an aging population, and the introduction of advanced regenerative therapies.

Regenerative medicine is a field of biomedical science focusing on repairing, replacing, or regenerating damaged or diseased cells, tissues, or organs to restore normal function. It combines approaches from stem cell therapy, tissue engineering, gene therapy, and biomaterials to promote healing and regeneration.

The regenerative medicine market in North America is segmented into the US, Canada, and Mexico. The US holds the largest market share, followed by Canada. According to the Centers for Disease Control and Prevention (CDC), a heart attack occurs every 40 seconds in the US, with approximately 805,000 people experiencing it each year. Cancer is a major cause of morbidity and mortality, with significant healthcare costs and quality-of-life implications. The rising prevalence of chronic and degenerative conditions is increasing the demand for novel treatment approaches such as regenerative therapies.

Regenerative medicine holds transformative potential for prevalent diseases in North America, particularly cardiovascular diseases, diabetes, and certain types of cancer. Advances in stem cell therapies, gene editing, and tissue engineering are showing promise in these areas. Several CAR-T cell therapies have received FDA approval for treating hematological malignancies, such as multiple myeloma and lymphoma.

The rising burden of chronic and degenerative diseases is driving investments in research, biomanufacturing, and workforce development within the regenerative medicine sector. This ecosystem fosters rapid innovation and enhances the availability and sophistication of treatment options. In January 2022, Cellino Biotech, Inc., a US-based autonomous cell therapy manufacturing company, completed an US$ 80 million Series A financing round led by Bayer AG's Leaps by Bayer, alongside 8VC and the Humboldt Fund. Cellino's innovative manufacturing platform combines artificial intelligence and laser technology to automate cell therapy production, aiming to lower costs and improve scalability. This investment offers Leaps by Bayer a unique opportunity to support the development of advanced therapies that enhance patient access to cell treatments.

In North America, the US holds a significant share of the regenerative medicine market. The US dominated the North America regenerative medicine market in 2024. According to the CDC, in 2023, 76.4% of US adults, over 194 million people, had at least one chronic condition. More than half of these individuals (51.4%, or 131 million) reported having two or more chronic conditions. The prevalence of at least one chronic condition among adults increased from 72.3% to 76.4%. The percentage of adults with two or more chronic conditions rose from 47.3% to 51.4%.

According to the Alzheimer's Association, by 2025, more than 7.2 million Americans aged 65 and older are projected to be living with Alzheimer's, with that number expected to grow to 12.7 million by 2050. Chronic illnesses such as cardiovascular diseases, cancer, and neurodegenerative disorders lead to irreversible damage to tissues or organs, making patients prime candidates for regenerative therapies such as stem cell therapy, tissue engineering, and gene therapy. Regenerative medicine shows promise in restoring lost heart function after heart attacks, regenerating cartilage in cases of degenerative joint diseases, and replacing damaged neurons in neurodegenerative disorders. In the US, MSCs are commonly used to treat degenerative diseases and certain diseases of the skin, bone, and cartilage.

The US government is promoting the development and approval of regenerative therapies by utilizing regulatory innovation, expedited approval processes, direct funding, and collaborative technical support. As of mid-2025, more than 80 Regenerative Medicine Advanced Therapy (RMAT) designations have been awarded, which have helped speed up clinical advancements for conditions such as spinal cord injuries and heart failure. In 2023, the US FDA approved cell and gene therapies, including gene-editing treatments targeting rare diseases. Therapies such as exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel for sickle cell disease, as well as valoctocogene roxaparvovec for severe hemophilia A, have received FDA approval, highlighting the potential of gene therapies in addressing rare disease challenges. Thus, the increasing incidence of chronic diseases, coupled with ongoing research and approval initiatives to promote the adoption of regenerative technologies, is fueling the market growth in the US.

Integration of Artificial Intelligence in Regenerative Medicine to Provide Market Opportunities in Future

Integrating artificial intelligence (AI) into regenerative medicine enhances drug discovery, improves personalized therapies, and accelerates development timelines. AI-driven technologies facilitate handling complex biological data and optimizing manufacturing processes, leading to more efficient regenerative therapies. Aspen Neuroscience's ANPD-001, currently in Phase II clinical trials for Parkinson's disease, exemplifies a pioneering AI-enabled regenerative therapy. This therapy utilizes AI and machine learning (ML) to reprogram patient skin cells into dopamine-producing neurons. Proprietary AI-based genomic tests ensure cell quality, resulting in safer, more personalized treatments. This approach demonstrates how AI validation can enhance the precision and biological safety of regenerative medicine products while reducing the risk of rejection.

Several startups illustrate this trend further. The Argentinian company MesencHyal-T employs AI-powered cellular therapies aimed at bone regeneration. It uses machine learning in its scalable production processes to standardize stem cell expansion and improve the osteogenic potential of the cells. Additionally, it collaborates with hospitals and research centers to facilitate quicker clinical deployment, showing how AI aids in discovery as well as real-world applications and outcome predictions. Similarly, the UK-based company Trogenix integrates genomics, bioinformatics, and machine learning into its synthetic super-enhancer viral immunotherapy for precise gene control and targeted regenerative treatments in cancer and age-related tissue repair.

AI-driven platforms contribute to product launches that accelerate drug candidate generation. Insilico Medicine, a leader in AI drug discovery, achieved a milestone with INS018_055, a small-molecule drug candidate for idiopathic pulmonary fibrosis. This drug is the first entirely AI-discovered and AI-designed medication to enter Phase II trials. Insilico's collaboration with pharmaceutical giant Sanofi, a US$1.2 billion deal, leverages Insilico's AI platform to identify novel targets and predict clinical outcomes, highlighting the ecosystem of partnerships centered around AI-driven regenerative solutions.

In manufacturing and therapy design, companies such as US-based Shinobi Therapeutics utilize AI-enabled platforms to develop immune-evasive induced pluripotent stem cell (iPSC) therapies, featuring genetic edits that evade immune detection. This strategy offers off-the-shelf regenerative treatments suitable for oncology, diabetes, and autoimmune disorders, showcasing how AI simplifies the complex genetic engineering required for advanced regenerative products.

AI helps overcome challenges in regenerative medicine, such as high developmental costs and lengthy timelines. It enhances predictive modeling, quality control, and scaling up production. AI algorithms analyze vast datasets to predict patient-specific responses to stem cell therapies, aiding in creating personalized treatment plans and improving clinical outcomes. Industry forecasts for 2025 suggest that AI adoption will increase dramatically, becoming foundational in personalizing regenerative protocols worldwide.

The integration of AI in regenerative medicine represents a groundbreaking trend. AI streamlines therapy development and enhances personalization, quality, and clinical effectiveness. This approach positions regenerative medicine for unprecedented growth and patient impact in the coming years, underscoring the convergence of cutting-edge technology with biological innovation to revolutionize the design, testing, and delivery of regenerative therapies.

The US Food and Drug Administration, Medicines and Healthcare Products Regulatory Agency (MHRA), Alliance for Regenerative Medicine (ARM) are among the primary and secondary sources referred to while preparing the regenerative medicine market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Regenerative Medicines Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Regenerative Medicines Market - Key Market Dynamics

  • 5.1 Regenerative Medicines Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Disorders and Aging Population
    • 5.2.2 Introduction of Advanced Regenerative Therapies
  • 5.3 Market Restraints
    • 5.3.1 High-Cost Barriers in Regeneration Treatment
  • 5.4 Market Opportunities
    • 5.4.1 Surging Demand for Personalized and Precision Medicine
  • 5.5 Future Trends
    • 5.5.1 Integration of Artificial Intelligence in Regenerative Medicine
  • 5.6 Impact of Drivers and Restraints:

6. Regenerative Medicines Market - Global Market Analysis

  • 6.1 Regenerative Medicines Market Revenue (US$ Million), 2021-2031
  • 6.2 Regenerative Medicines Market Forecast Analysis

7. Regenerative Medicines Market Analysis - by Product Type

  • 7.1 Cell Based Products
    • 7.1.1 Overview
    • 7.1.2 Cell Based Products: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
        • 7.1.2.1.1 Global: Regenerative Medicines Market Breakdown, by Cell Based Products
  • 7.2 Gene Therapy
    • 7.2.1 Overview
    • 7.2.2 Gene Therapy: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Tissue Engineering
    • 7.3.1 Overview
    • 7.3.2 Tissue Engineering: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)

8. Regenerative Medicines Market Analysis - by Application

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Oncology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Neurological Disorders
    • 8.2.1 Overview
    • 8.2.2 Neurological Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Wound Healing and Skin Regeneration
    • 8.3.1 Overview
    • 8.3.2 Wound Healing and Skin Regeneration: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Ophthalmology
    • 8.4.1 Overview
    • 8.4.2 Ophthalmology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Orthopedics and Musculoskeletal
    • 8.5.1 Overview
    • 8.5.2 Orthopedics and Musculoskeletal: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Immunology
    • 8.6.1 Overview
    • 8.6.2 Immunology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Genetic Disorders
    • 8.7.1 Overview
    • 8.7.2 Genetic Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)

9. Regenerative Medicines Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Regenerative Medicines Market Overview
    • 9.1.2 North America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.1.2.1 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.1.2.2 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.1.2.3 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.1.3 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.1.3.1 United States: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.3.1.1 United States: Regenerative Medicines Market Breakdown, by Product Type
        • 9.1.3.1.2 United States: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.1.3.1.3 United States: Regenerative Medicines Market Breakdown, by Application
      • 9.1.3.2 Canada: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.3.2.1 Canada: Regenerative Medicines Market Breakdown, by Product Type
        • 9.1.3.2.2 Canada: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.1.3.2.3 Canada: Regenerative Medicines Market Breakdown, by Application
      • 9.1.3.3 Mexico: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.3.3.1 Mexico: Regenerative Medicines Market Breakdown, by Product Type
        • 9.1.3.3.2 Mexico: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.1.3.3.3 Mexico: Regenerative Medicines Market Breakdown, by Application
  • 9.2 Europe
    • 9.2.1 Europe Regenerative Medicines Market Overview
    • 9.2.2 Europe: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.2.2.1 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.2.2.2 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.2.2.3 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.2.3 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.2.3.1 Germany: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.1.1 Germany: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.1.2 Germany: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.1.3 Germany: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.2 United Kingdom: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.2.1 United Kingdom: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.2.2 United Kingdom: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.2.3 United Kingdom: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.3 France: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.3.1 France: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.3.2 France: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.3.3 France: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.4 Italy: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.4.1 Italy: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.4.2 Italy: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.4.3 Italy: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.5 Spain: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.5.1 Spain: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.5.2 Spain: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.5.3 Spain: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.6 Rest of Europe: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.6.1 Rest of Europe: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.6.2 Rest of Europe: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.6.3 Rest of Europe: Regenerative Medicines Market Breakdown, by Application
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Regenerative Medicines Market Overview
    • 9.3.2 Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.3.2.1 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.3.2.2 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.3.2.3 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.3.3 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.3.3.1 China: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.1.1 China: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.1.2 China: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.1.3 China: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.2 Japan: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.2.1 Japan: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.2.2 Japan: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.2.3 Japan: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.3 India: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.3.1 India: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.3.2 India: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.3.3 India: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.4 Australia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.4.1 Australia: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.4.2 Australia: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.4.3 Australia: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.5 South Korea: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.5.1 South Korea: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.5.2 South Korea: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.5.3 South Korea: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.6 Rest of APAC: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.6.1 Rest of APAC: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.6.2 Rest of APAC: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.6.3 Rest of APAC: Regenerative Medicines Market Breakdown, by Application
  • 9.4 Middle East and Africa
    • 9.4.1 Middle East and Africa Regenerative Medicines Market Overview
    • 9.4.2 Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.4.2.1 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.4.2.2 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.4.2.3 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.4.3 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 Saudi Arabia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.1.1 Saudi Arabia: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.1.2 Saudi Arabia: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.1.3 Saudi Arabia: Regenerative Medicines Market Breakdown, by Application
      • 9.4.3.2 United Arab Emirates: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.2.1 United Arab Emirates: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.2.2 United Arab Emirates: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.2.3 United Arab Emirates: Regenerative Medicines Market Breakdown, by Application
      • 9.4.3.3 South Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.3.1 South Africa: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.3.2 South Africa: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.3.3 South Africa: Regenerative Medicines Market Breakdown, by Application
      • 9.4.3.4 Rest of Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.4.1 Rest of Middle East and Africa: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.4.2 Rest of Middle East and Africa: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.4.3 Rest of Middle East and Africa: Regenerative Medicines Market Breakdown, by Application
  • 9.5 South and Central America
    • 9.5.1 South and Central America Regenerative Medicines Market Overview
    • 9.5.2 South and Central America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.5.2.1 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.5.2.2 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.5.2.3 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.5.3 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.1 Brazil: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.1.1 Brazil: Regenerative Medicines Market Breakdown, by Product Type
        • 9.5.3.1.2 Brazil: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.5.3.1.3 Brazil: Regenerative Medicines Market Breakdown, by Application
      • 9.5.3.2 Argentina: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.2.1 Argentina: Regenerative Medicines Market Breakdown, by Product Type
        • 9.5.3.2.2 Argentina: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.5.3.2.3 Argentina: Regenerative Medicines Market Breakdown, by Application
      • 9.5.3.3 Rest of South and Central America: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.3.1 Rest of South and Central America: Regenerative Medicines Market Breakdown, by Product Type
        • 9.5.3.3.2 Rest of South and Central America: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.5.3.3.3 Rest of South and Central America: Regenerative Medicines Market Breakdown, by Application

10. Competitive Landscape

  • 10.1 Heat Map Analysis by Key Players
  • 10.2 Company Positioning & Concentration

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Product Launch, Product Approvals
  • 11.3 Expansions And Other Strategic Developments

12. Company Profiles

  • 12.1 Bristol-Myers Squibb Co
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Novartis AG
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Daiichi Sankyo Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Takeda Pharmaceutical Co Ltd
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Japan Tissue Engineering Co., Ltd.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Bluebird Bio Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 JCR Pharmaceuticals Co. Ltd.
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Vertex Pharmaceuticals Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Ferring Pharmaceuticals
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 CSL Behring LLC
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments
  • 12.12 BioMarin Pharmaceutical Inc.
    • 12.12.1 Key Facts
    • 12.12.2 Business Description
    • 12.12.3 Products and Services
    • 12.12.4 Financial Overview
    • 12.12.5 SWOT Analysis
    • 12.12.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Regenerative Medicines Market Segmentation
  • Table 2. Global: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 3. Global: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 4. North America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 5. North America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 6. North America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 7. North America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 8. North America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 9. North America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 10. United States: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 11. United States: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 12. United States: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 13. United States: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 14. United States: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 15. United States: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 16. Canada: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 17. Canada: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 18. Canada: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 19. Canada: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 20. Canada: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 21. Canada: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 22. Mexico: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 23. Mexico: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 24. Mexico: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 25. Mexico: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 26. Mexico: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 27. Mexico: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 28. Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 29. Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 30. Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 31. Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 32. Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 33. Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 34. Germany: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 35. Germany: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 36. Germany: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 37. Germany: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 38. Germany: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 39. Germany: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 40. United Kingdom: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 41. United Kingdom: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 42. United Kingdom: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 43. United Kingdom: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 44. United Kingdom: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 45. United Kingdom: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 46. France: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 47. France: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 48. France: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 49. France: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 50. France: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 51. France: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 52. Italy: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 53. Italy: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 54. Italy: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 55. Italy: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 56. Italy: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 57. Italy: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 58. Spain: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 59. Spain: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 60. Spain: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 61. Spain: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 62. Spain: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 63. Spain: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 64. Rest of Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 65. Rest of Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 66. Rest of Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 67. Rest of Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 68. Rest of Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 69. Rest of Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 70. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 71. Asia Pacific: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 72. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 73. Asia Pacific: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 74. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 75. Asia Pacific: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 76. China: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 77. China: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 78. China: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 79. China: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 80. China: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 81. China: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 82. Japan: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 83. Japan: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 84. Japan: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 85. Japan: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 86. Japan: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 87. Japan: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 88. India: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 89. India: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 90. India: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 91. India: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 92. India: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 93. India: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 94. Australia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 95. Australia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 96. Australia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 97. Australia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 98. Australia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 99. Australia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 100. South Korea: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 101. South Korea: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 102. South Korea: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 103. South Korea: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 104. South Korea: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 105. South Korea: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 106. Rest of APAC: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 107. Rest of APAC: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 108. Rest of APAC: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 109. Rest of APAC: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 110. Rest of APAC: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 111. Rest of APAC: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 112. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 113. Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 114. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 115. Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 116. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 117. Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 118. Saudi Arabia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 119. Saudi Arabia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 120. Saudi Arabia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 121. Saudi Arabia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 122. Saudi Arabia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 123. Saudi Arabia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 124. United Arab Emirates: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 125. United Arab Emirates: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 126. United Arab Emirates: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 127. United Arab Emirates: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 128. United Arab Emirates: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 129. United Arab Emirates: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 130. South Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 131. South Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 132. South Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 133. South Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 134. South Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 135. South Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 136. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 137. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 138. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 139. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 140. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 141. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 142. South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 143. South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 144. South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 145. South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 146. South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 147. South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 148. Brazil: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 149. Brazil: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 150. Brazil: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 151. Brazil: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 152. Brazil: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 153. Brazil: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 154. Argentina: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 155. Argentina: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 156. Argentina: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 157. Argentina: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 158. Argentina: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 159. Argentina: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 160. Rest of South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 161. Rest of South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 162. Rest of South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 163. Rest of South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 164. Rest of South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 165. Rest of South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 166. Heat Map Analysis by Key Players
  • Table 167. Glossary of Terms, Regenerative Medicine Market

List Of Figures

  • Figure 1. Regenerative Medicines Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Regenerative Medicines Market Revenue (US$ Million), 2021-2031
  • Figure 5. Regenerative Medicines Market Revenue (US$ Million), 2021-2031
  • Figure 6. Regenerative Medicines Market Share (%) - by Product Type (2024 and 2031)
  • Figure 7. Cell Based Products: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Gene Therapy: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Tissue Engineering: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Regenerative Medicines Market Share (%) - by Application (2024 and 2031)
  • Figure 11. Oncology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Neurological Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Wound Healing and Skin Regeneration: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Ophthalmology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Orthopedics and Musculoskeletal: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Immunology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Genetic Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. North America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 20. North America: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 21. United States: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Canada: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. Mexico: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Europe: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 25. Europe: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 26. Germany: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. United Kingdom: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. France: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 29. Italy: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 30. Spain: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Rest of Europe: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 33. Asia Pacific: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 34. China: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Japan: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. India: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 37. Australia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 38. South Korea: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 39. Rest of APAC: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 40. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 41. Middle East and Africa: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 42. Saudi Arabia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 43. United Arab Emirates: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 44. South Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. South and Central America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 47. South and Central America: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 48. Brazil: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 49. Argentina: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 50. Rest of South and Central America: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 51. Company Positioning & Concentration